Check Cap Ltd (NASDAQ:CHEK) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 589,900 shares, a growth of 7.2% from the September 30th total of 550,500 shares. Approximately 8.2% of the company’s stock are short sold. Based on an average daily trading volume, of 43,800 shares, the short-interest ratio is currently 13.5 days.
NASDAQ:CHEK traded down $0.02 during mid-day trading on Friday, reaching $1.51. The stock had a trading volume of 81,500 shares. The business’s 50 day moving average is $1.82 and its 200 day moving average is $2.09. Check Cap has a fifty-two week low of $1.35 and a fifty-two week high of $4.20.
Check Cap (NASDAQ:CHEK) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.42). As a group, sell-side analysts forecast that Check Cap will post -1.73 earnings per share for the current fiscal year.
Separately, Zacks Investment Research downgraded Check Cap from a “hold” rating to a “sell” rating in a report on Wednesday, November 6th.
A hedge fund recently raised its stake in Check Cap stock. Renaissance Technologies LLC raised its stake in shares of Check Cap Ltd (NASDAQ:CHEK) by 24.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 307,468 shares of the medical research company’s stock after acquiring an additional 60,026 shares during the quarter. Renaissance Technologies LLC owned approximately 19.16% of Check Cap worth $652,000 as of its most recent filing with the SEC.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: How to Invest in Growth Stocks
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.